Future Directions: Toward Personalized EGFR Therapy in NSCLC

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, reflect on whether the field is becoming more biologically or data driven, concluding that both are increasingly intertwined. They discuss the move toward molecularly informed personalization, key unanswered questions around identifying patients who benefit most from intensification, and the need for better biomarkers to guide safe treatment de-escalation.